{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:14:53Z","timestamp":1783606493018,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MFE-187912"],"award-info":[{"award-number":["MFE-187912"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["2023\\u20132026"],"award-info":[{"award-number":["2023\\u20132026"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pharmthera.2026.109057","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:53:02Z","timestamp":1780717982000},"page":"109057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Incretin-based therapies: Effects on plasma lipids and potential mechanisms"],"prefix":"10.1016","volume":"285","author":[{"given":"Majid M.","family":"Syed-Abdul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary F.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2026.109057_bb0005","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The Gluco- and Liporegulatory and vasodilatory effects of glucose-dependent Insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0010","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/jc.2016-1933","article-title":"Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans","volume":"101","author":"Asmar","year":"2016","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0015","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2337\/db10-0098","article-title":"Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans","volume":"59","author":"Asmar","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2010.04.024","article-title":"One-year treatment with exenatide vs. insulin glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress","volume":"212","author":"Bunck","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0030","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0035","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/17512433.2024.2363838","article-title":"Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A systematic review and network meta-analysis","volume":"17","author":"Chae","year":"2024","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fendo.2019.00080","article-title":"Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes","volume":"10","author":"Deacon","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.pharmthera.2026.109057_bb0045","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/db23-0972","article-title":"GLP-1 receptor agonist treatment improves fasting and postprandial Lipidomic profiles independently of diabetes and weight loss","volume":"73","author":"Della Pepa","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11883-025-01288-w","article-title":"Remnant cholesterol: Should it be a target for prevention of ASCVD?","volume":"27","author":"Doi","year":"2025","journal-title":"Current Atherosclerosis Reports"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0055","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: From basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00125-011-2447-3","article-title":"Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and\/or pioglitazone: A randomised double-blind placebo-controlled study","volume":"55","author":"Eliasson","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0065","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/ATVBAHA.114.304873","article-title":"Central nervous system regulation of intestinal lipoprotein metabolism by glucagon-like Peptide-1 via a brain-gut Axis","volume":"35","author":"Farr","year":"2015","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0080","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0085","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0090","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation 2019"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0095","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0100","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12133","article-title":"Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial","volume":"15","author":"Hermansen","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0105","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109057_bb0110","first-page":"301","article-title":"Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism","volume":"2024","author":"Hoffman","year":"2021","journal-title":"Medicina em Revista"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0115","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0120","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1038\/s41598-017-06031-3","article-title":"Development and characterization of a novel Prox1-EGFP lymphatic and Schlemm\u2019s canal reporter rat","volume":"7","author":"Jung","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0125","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0130","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0140","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/dom.15365","article-title":"Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes","volume":"26","author":"Mather","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0145","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00125-006-0340-2","article-title":"Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes","volume":"49","author":"Matikainen","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dom.13487","article-title":"Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-Centre randomized controlled study","volume":"21","author":"Matikainen","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0155","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/dme.12094","article-title":"The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes","volume":"30","author":"Matikainen","year":"2013","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0160","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1210\/jc.2003-030049","article-title":"Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes","volume":"88","author":"Meier","year":"2003","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0165","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00125-005-0126-y","article-title":"Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans","volume":"49","author":"Meier","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12325-011-0088-z","article-title":"DPP-4 inhibitors and lipids: Systematic review and meta-analysis","volume":"29","author":"Monami","year":"2012","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0175","doi-asserted-by":"crossref","first-page":"8537","DOI":"10.1038\/s41598-019-44885-x","article-title":"Randomized evaluation of anagliptin vs Sitagliptin on low-density lipoproteiN cholesterol in diabetes (REASON) trial: A 52-week, open-label, randomized clinical trial","volume":"9","author":"Morimoto","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1358625","article-title":"GLP-2 regulation of intestinal lipid handling","volume":"15","author":"Mukherjee","year":"2024","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0185","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/ATVBAHA.121.316311","article-title":"GLP-1 (glucagon-like Peptide-1) is physiologically relevant for chylomicron secretion beyond its known pharmacological role","volume":"41","author":"Nahmias","year":"2021","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0190","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0195","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0200","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with Tirzepatide versus Dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1475-2840-12-8","article-title":"Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: A preliminary report","volume":"12","author":"Noda","year":"2013","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0210","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0215","first-page":"347","article-title":"Management of Hypertriglyceridemia: Common questions and answers","volume":"102","author":"Oh","year":"2020","journal-title":"American Family Physician"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0220","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0225","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0230","doi-asserted-by":"crossref","first-page":"G943","DOI":"10.1152\/ajpgi.00303.2004","article-title":"GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats","volume":"288","author":"Qin","year":"2005","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2024.06.012","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0240","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.EI20008AH5C","article-title":"Diagnosing and treating insomnia in adults and older adults","volume":"82","author":"Rosenberg","year":"2021","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0250","article-title":"GLP-1R agonism directly improves the pumping capacity of murine collecting lymphatic vessels","author":"Schulz","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0255","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2010.05.028","article-title":"Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus","volume":"212","author":"Schwartz","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0260","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0265","first-page":"844","article-title":"ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk","volume":"19","author":"Sehayek","year":"2025","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0270","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00018-024-05507-6","article-title":"GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells","volume":"81","author":"da Silva Lima","year":"2024","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2014.11.008","article-title":"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: A systematic review and network meta-analysis","volume":"37","author":"Sun","year":"2015","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/metabo14010012","article-title":"Lipid metabolism in metabolic-associated Steatotic liver disease (MASLD)","volume":"14","author":"Syed-Abdul","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0285","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1016\/j.tjnut.2023.09.018","article-title":"Isotope labeling and biochemical assessment of liver-triacylglycerol in patients with different levels of histologically-graded liver disease","volume":"153","author":"Syed-Abdul","year":"2023","journal-title":"The Journal of Nutrition"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0290","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities","volume":"72","author":"Syed-Abdul","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0295","article-title":"Glucagon-like peptide-2 mobilization of intestinal lipid does not require canonical enterocyte chylomicron synthetic machinery","volume":"1867","author":"Syed-Abdul","year":"2022","journal-title":"Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0300","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1210\/clinem\/dgac690","article-title":"Glucagon-like Peptide-2 acutely enhances chylomicron secretion in humans without mobilizing cytoplasmic lipid droplets","volume":"108","author":"Syed-Abdul","year":"2023","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0305","first-page":"954","article-title":"Glucagon-like-Peptide-2 stimulates lacteal contractility and enhances chylomicron transport in the presence of an intact enteric nervous system","volume":"3","author":"Syed-Abdul","year":"2024","journal-title":"Gastro Hepatology Advances"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0310","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/MOL.0000000000000821","article-title":"Lymphatics - not just a chylomicron conduit","volume":"33","author":"Syed-Abdul","year":"2022","journal-title":"Current Opinion in Lipidology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0315","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/dom.14328","article-title":"Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes","volume":"23","author":"Taskinen","year":"2021","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0320","article-title":"Activation of VEGFR3 and MLC2 are critical for GLP-2 enhancement of chylomicron transport","volume":"4","author":"Tian","year":"2025","journal-title":"Gastro Hepatology Advances"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0325","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1463-1326.2011.01362.x","article-title":"Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes","volume":"13","author":"Tremblay","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0330","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.12359","article-title":"Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes","volume":"16","author":"Tremblay","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0335","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc20-1843","article-title":"Liraglutide increases the catabolism of apolipoprotein B100-containing lipoproteins in patients with type 2 diabetes and reduces Proprotein convertase Subtilisin\/Kexin type 9 expression","volume":"44","author":"Verges","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0340","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1161\/ATVBAHA.118.310990","article-title":"Liraglutide reduces postprandial hyperlipidemia by increasing ApoB48 (apolipoprotein B48) catabolism and by reducing ApoB48 production in patients with type 2 diabetes mellitus","volume":"38","author":"Verges","year":"2018","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0345","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0350","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1210\/jc.2018-01176","article-title":"Lixisenatide reduces chylomicron triacylglycerol by increased clearance","volume":"104","author":"Whyte","year":"2019","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0355","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0360","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/dom.14174","article-title":"The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes","volume":"22","author":"Wilson","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0365","first-page":"1366","article-title":"ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Writing C","year":"2022","journal-title":"Journal of the American College of Cardiology 2022"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0370","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1161\/ATVBAHA.112.246207","article-title":"Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans","volume":"32","author":"Xiao","year":"2012","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0375","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.2337\/db13-1654","article-title":"Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans","volume":"63","author":"Xiao","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2026.109057_bb0380","first-page":"1","article-title":"Dipeptidyl Peptidase-4 inhibitors improved lipid levels in patients with type 2 diabetes: A Meta-analysis of randomized clinical trials","volume":"00","author":"Zhao","year":"2025","journal-title":"Nutrition Reviews"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:24:21Z","timestamp":1783603461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":76,"alternative-id":["S0163725826000847"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109057","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incretin-based therapies: Effects on plasma lipids and potential mechanisms","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109057"}}